Navigation Links
InterMune to Present at Deutsche Bank Biotech Boston Confab
Date:11/7/2008

BRISBANE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Deutsche Bank's 2008 Biotech Boston Confab on November 11, 2008 at 4:00 p.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
2. InterMune to Release Third Quarter 2008 Financial Results on November 6
3. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
4. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
5. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
8. InterMune to Present at BMO Healthcare Conference
9. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
10. InterMune to Present at Jefferies Healthcare Conference
11. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... ... ... Apex Therapeutics announced today that company CEO, David Broecker provided a company ... presentation took place on Tuesday, June 16 and provided an update on the achievement ... treatment of pancreatic cancer. A copy of the company overview can be found ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty ... the first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty ... this course combines students from both universities and is taught on both continents. ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... Dec. 15 A panel of expert judges selected Nikon ... as second place among the top ten in The ... combinations of invention, vision and utility. The award, the ... market in the past year, acknowledges Nikon,s exclusive PFS system ...
... Mass., Dec. 15 Boston Scientific,Corporation (NYSE: ... Drug,Administration (FDA) has approved the Express(R) SD Renal Monorail(R),Premounted ... (percutaneous,transluminal renal angioplasty) in certain lesions of the renal ... pre-mounted stent approved for use,in renal arteries in the ...
... bwin, the world,s,leading online gaming company, and the Division ... School Teaching Affiliate, have,just signed an agreement for research ... scientific evidence to create the safest,possible online gaming environment ... , The Division ...
Cached Biology Technology:Nikon Instruments Perfect Focus System Wins Second Place in The Scientist's Top Innovations of 2008 Award 2FDA Approves Boston Scientific's Express(R) SD Renal Stent System 2FDA Approves Boston Scientific's Express(R) SD Renal Stent System 3FDA Approves Boston Scientific's Express(R) SD Renal Stent System 4bwin and Harvard Medical School Faculty Sign 5-Year Research Cooperation Agreement 2
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... Access to Research Careers) Program has announced the travel ... Conference (GLBIO) to be held at Ohio University in ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... ON When you think you see a face in the ... seems to be upside down. It turns out the answer ... wired not to. Using tests of visual perception and functional ... of Western Ontario,s world-renowned Centre for Brain & Mind recently measured ...
... Mention vitamin D-fortified foods and most people think of ... since the 1930s. A new episode in the American ... says that vitamin D-fortified bread could join milk as ... difficult to get naturally in foods. The ...
Cached Biology News:
Protein Marker Detection Pack contains biotinylate...
...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
Biology Products: